(Approval lapsed) Captopril 25mg/5mL Sugar free oral solution (Syrimed)

HYPERTENSION: Captopril is indicated for the treatment of hypertension.

In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis.

Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.

MYOCARDIAL INFARCTION: Captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40% and to reduce the incidence of overt heart failure, and subsequent hospitalisations for congestive heart failure in these patients. The efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct.

HEART FAILURE: Captopril is indicated for the treatment of heart failure. In symptomatic patients it is recommended that captopril be administered together with a diuretic.

DIABETIC NEPHROPATHY: Captopril is indicated for the treatment of diabetic nephropathy in patients with Type 1 insulin-dependent diabetes mellitus.